Nanobiotix S.A.

NASDAQ:NBTX

Biotechnology

Healthcare
$26.90 -0.91%

-$0.33 today

Market cap
$1.37B
Beta
0.59
P/E (TTM)
-60.2
EPS (TTM)
-$0.51
52W Low $4.31High $57.14

Volume 0.04M

Average 0.08M

NBTX Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Nanobiotix S.A.NASDAQ: NBTX

Retained Earnings · Q4 FY2025 · quarter ended Dec 2025

Retained earnings remains negative

Q4 FY2025 retained earnings was -€23.96M, compared with -€68.13M a year earlier.

Context

  • Retained earnings amounted to 35.4% of total assets at the end of Q4 FY2025, down 65.7 pp from a year earlier.
  • Retained earnings grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps rising in the next quarterly balance sheet after a +64.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
-€23.96M— QoQ
Last fiscal yearDec 2025
-€23.96M+64.8% YoY
Year agoDec 2024
-€68.13M+64.8% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+64.8%——
1 year+64.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

EUR · from the balance sheet

Latest · FY2025
(23.96M) EUR
Year-over-year change
+64.8%

Retained Earnings vs competitors

How NBTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +64.8% is the highest of 11, against a peer median of -30.6%.
  • Retained earnings amounts to 35.4% of total assets for NBTX, versus a peer median of 259.5%.
NBTX Competitors
Retained Earnings for NBTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NBTXNanobiotix S.A.Dec 2025-€23.96M EUR+64.8%—35.4%
NVCTNuvectis Pharma, Inc.Mar 2026-$105.74M USD-34.6%—416.3%
IMMXImmix Biopharma, Inc.Mar 2026-$114.55M USD-44.0%—119.6%
CADLCandel Therapeutics, Inc.Mar 2026-$239.25M USD-29.4%—118.5%
TYRATyra Biosciences, Inc.Mar 2026-$410.56M USD-46.9%—99.6%
AVBPArriVent BioPharma, Inc. Common StockMar 2026-$447.96M USD-48.0%—128.2%
BDTXBlack Diamond Therapeutics, Inc.Mar 2026-$473.78M USD-10.0%—356.4%
KURAKura Oncology, Inc.Mar 2026-$1.25B USD-30.9%—191.2%
PBYIPuma Biotechnology, Inc.Mar 2026-$1.29B USD+1.9%—668.2%
SNDXSyndax Pharmaceuticals, Inc.Mar 2026-$1.55B USD-18.6%—327.8%
IBRXImmunityBio, Inc.Sep 2026-$4.77B USD-30.3%—783.5%
Peer median (excluding NBTX) —-30.6%—259.5%

Competitors are the stored peer set for NBTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents83.92M41.39M75.28M49.74M52.75M
Short-term Investments00000
Net Receivables3.89M2.84M2.97M8.54M7.68M
Inventory02.98M200K00
Other Current Assets3.04M2.17M6.33M(1K)2K
Total Current Assets93.06M52.36M87.34M61.47M62.75M
Property, Plant & Equipment (Net)8.19M7.12M6.11M5.54M4.57M
Goodwill00000
Intangible Assets4K1K8K7K10K
Long-term Investments98K0000
Tax Assets00000
Other Non-current Assets421K291K443K406K434K
Total Non-current Assets8.71M7.41M6.56M5.95M5.01M
Total Assets101.77M59.77M93.9M67.42M67.76M
Account Payables5M4M6.7M4.48M6.58M
Short-term Debt7.08M3.6M3.82M3.66M3.1M
Tax Payables5.08M6.6M7.38M6.87M6.82M
Deferred Revenue16.77M16.57M18.23M18.16M36.22M
Other Current Liabilities5.39M7.41M760K8.27M430K
Total Current Liabilities36.85M37.94M49.87M58.94M57.51M
Long-term Debt32.42M44.04M41.66M43.01M89.12M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities318K270K325K28.21M3.73M
Total Non-current Liabilities38.13M48.88M45.87M74.19M94.74M
Total Liabilities74.98M86.81M95.74M133.12M152.24M
Common Stock1.05M1.05M1.41M1.42M1.45M
Retained Earnings(47M)(57.04M)(39.7M)(68.13M)(23.96M)
Accumulated OCI(182.82M)(226.58M)(276.07M)(311.51M)(376.15M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity26.79M(27.05M)(1.84M)(65.7M)(84.48M)
Total Debt46.02M53.17M50.57M50.9M95.32M
Net Debt(37.9M)11.78M(24.72M)1.17M42.57M

Nanobiotix S.A.

NASDAQ:NBTX

Intrinsic Alpha fair value

Locked

Current Price

$26.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.